Coloplast sales rise 20%, profits 61%
This article was originally published in Clinica
Danish medical device manufacturer Coloplast reported sales up 20% in the six months to the end of March to DKr 936.9 million ($160 million). Excluding skincare products sales from US subsidiary Sween, which was acquired in early 1995, Coloplast's sales rose 13%. Pre-tax profit in the first six months was DKr 110 million, up 61%. The strongest sales growth was seen in woundcare, up 24%, followed by incontinence products, up 19%, and ostomy sales, up 13%. Sales of breast care products increased 8%. Coloplast has confirmed earlier forecasts of sales and profit growth of more than 15% during fiscal 1996.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.